Literature DB >> 21427705

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Phong Trang1, Jason F Wiggins, Christopher L Daige, Chris Cho, Michael Omotola, David Brown, Joanne B Weidhaas, Andreas G Bader, Frank J Slack.   

Abstract

MicroRNAs (miRNAs) are emerging as potential cancer therapeutics, but effective delivery mechanisms to tumor sites are a roadblock to utility. Here we show that systemically delivered, synthetic miRNA mimics in complex with a novel neutral lipid emulsion are preferentially targeted to lung tumors and show therapeutic benefit in mouse models of lung cancer. Therapeutic delivery was demonstrated using mimics of the tumor suppressors, microRNA-34a (miR-34a) and let-7, both of which are often down regulated or lost in lung cancer. Systemic treatment of a Kras-activated autochthonous mouse model of non-small cell lung cancer (NSCLC) led to a significant decrease in tumor burden. Specifically, mice treated with miR-34a displayed a 60% reduction in tumor area compared to mice treated with a miRNA control. Similar results were obtained with the let-7 mimic. These findings provide direct evidence that synthetic miRNA mimics can be systemically delivered to the mammalian lung and support the promise of miRNAs as a future targeted therapy for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427705      PMCID: PMC3129804          DOI: 10.1038/mt.2011.48

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  34 in total

1.  A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice.

Authors:  R H Brown; D M Walters; R S Greenberg; W Mitzner
Journal:  J Appl Physiol (1985)       Date:  1999-12

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  Adenovirus p53 gene therapy.

Authors:  Jack A Roth
Journal:  Expert Opin Biol Ther       Date:  2006-01       Impact factor: 4.388

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 5.  Cancer gene therapy: fringe or cutting edge?

Authors:  F McCormick
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

6.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

Review 7.  The promise of microRNA replacement therapy.

Authors:  Andreas G Bader; David Brown; Matthew Winkler
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

8.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Authors:  Charles N Landen; Arturo Chavez-Reyes; Corazon Bucana; Rosemarie Schmandt; Michael T Deavers; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

9.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 10.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

View more
  264 in total

Review 1.  Non-coding RNAs in cancer initiation and progression and as novel biomarkers.

Authors:  S Patrick Nana-Sinkam; Carlo M Croce
Journal:  Mol Oncol       Date:  2011-10-31       Impact factor: 6.603

2.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

Review 3.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

4.  Taming endothelial activation with a microRNA.

Authors:  Jason E Fish; Myron I Cybulsky
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

5.  A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA.

Authors:  Hemant Suryawanshi; Mayuresh Anant Sarangdhar; Manika Vij; Reema Roshan; Vijay Pal Singh; Munia Ganguli; Beena Pillai
Journal:  J Vis Exp       Date:  2015-12-26       Impact factor: 1.355

Review 6.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

7.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

8.  A simple high-throughput technology enables gain-of-function screening of human microRNAs.

Authors:  Wen-Chih Cheng; Tami J Kingsbury; Sarah J Wheelan; Curt I Civin
Journal:  Biotechniques       Date:  2013-02       Impact factor: 1.993

9.  microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.

Authors:  Zhenze Zhao; Xiuye Ma; Derek Sung; Monica Li; Adam Kosti; Gregory Lin; Yidong Chen; Alexander Pertsemlidis; Tzu-Hung Hsiao; Liqin Du
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 10.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.